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Abstract
The aim of this work is to develop a prokaryotic system capable of expressing membrane-bound receptors in quantities suitable for
biochemical and biophysical studies. Our strategy exploits the endogenous high-level expression of the membrane protein bacteriorhodopsin
(BR) in the Archaeon Halobacterium salinarum. We attempted to express the human muscarinic acetylcholine (M1) and adrenergic (a2b)
receptors by fusing the coding region of the m1 and a2b genes to nucleotide sequences known to direct bacterio-opsin (bop) gene
transcription. The fusions included downstream modifications to produce non-native carboxyl-terminal amino acids useful for protein
identification and purification. bop mRNA and BR accumulation were found to be tightly coupled and the carboxyl-terminal coding region
modifications perturbed both. m1 and a2b mRNA levels were low, and accumulation was sensitive to both the extent of the bop gene fusion
and the specific carboxyl-terminal coding sequence modifications included. Functional a2b adrenergic receptor expression was observed to
be dependent on the downstream coding region. This work demonstrates that a critical determinant of expression resides in the downstream
coding region of the wild-type bop gene and manipulation of the downstream coding region of heterologous genes may affect their potential
for expression in H. salinarum.
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1. Introduction
G protein-coupled receptors (GPCRs) make up the larg-
est gene family identified in eukaryotes [1]. Upon their
activation by endogenous ligands or drugs, these receptors
interact with G proteins to produce a signal transduction
cascade [2], which mediates cellular responses [3]. GPCRs
have superficial structural homology with bacteriorhodopsin
(BR) in that they have a core of seven transmembrane
antiparallel a-helices [4].
Current understanding of GPCR function is limited by
knowledge of the structural changes in receptors that lead to
G protein coupling. Most GPCR structural analyses have
relied on sequence homology alignments [4–6], predictive
secondary structural algorithms [7], or molecular engineer-
ing approaches [8–11]. Atomic resolution correlates of the
pathway of receptor activation are available only for BR and
rhodopsin [12,13]. Structural analyses that could reveal
ligand binding determinants and confirm the existence of
functional GPCR substates have not been possible because
protein expression systems do not generate adequate quan-
tities of GPCRs [14–16]. For this reason, this laboratory has
endeavored to develop a prokaryotic GPCR expression
system that exploits the naturally high levels of expression
of the bacterio-opsin gene (bop).
The bop gene is highly expressed in the Archaeon Hal-
obacterium salinarum. The bacterio-opsin protein (Bop)
couples with the chromophore retinal in a 1:1 stoichiometric
ratio [17]. This complex was named bacteriorhodopsin (BR)
because, at the time of its discovery, the only other known
retinal binding protein was the visual pigment rhodopsin [17].
BR accumulates to levels as high as 15–30 mg/l cell culture
and forms a specialized brightly colored membrane (the
purple membrane, PM; Ref. [18]). The PM is densely packed,
contains 10 lipid molecules per BR monomer, and sponta-
neously forms two-dimensional crystalline lattices in vivo
which facilitate BR purification, functional and structural
analyses [18,19].
Some of the most dramatic successes in membrane
protein expression have resulted from expression of BR
homologues in H. salinarum. Under the control of the bop
gene promoter, numerous BR mutants, halorhodopsin and
sensory rhodopsins have been expressed in functional form
in yields of 0.5–30 mg protein/l culture [20–23]. Because
H. salinarum membranes can accommodate very high levels
of BR and its homologues, this organism may be suited for
expressing non-native seven membrane spanning proteins.
Exploiting this expression system is feasible since the bop
gene has been cloned [24] and some molecular determinants
of bop gene expression have been characterized. The bop
gene transcriptional promoter, putative regulatory factor
binding sites, and transcriptional terminator have been
identified [25–27]. Translational regulation of bacterio-
opsin, via a signal recognition particle-dependent mecha-
nism, has also been demonstrated [28]. This membrane
targeting sequence may be specific to BR and related
homologues, because comparison of the pre-sequences of
six halo-archaeal integral membrane proteins revealed a
unique motif among the retinal binding proteins [28].
The goal of the current work is to understand how the
bop gene coding region contributes to high-level accumu-
lation of BR and to apply that insight in the expression of
the M1 subtype of the human muscarinic acetylcholine
receptor (mAChR) and human a2b adrenergic receptor
(a2bAR). mAChRs monitor activity of the neurotransmitter
acetylcholine in the central and parasympathetic nervous
systems. The muscarinic family of receptors is comprised of
five subtypes (M1–M5). The odd-numbered subtypes inter-
act with pertussis toxin-insensitive G proteins, stimulate
phospholipase C, promote calcium release from cytoplasmic
stores, modulate the activity of ion channels, and stimulate
mitogenesis [29,30]. The a2bARs also belong to the GPCR
superfamily. Three human a2-AR subtypes are known: a2A,
a2B and a2C [31]. All a2bARs couple to inhibition of
adenylyl cyclase and ion channel regulation through the
pertussis toxin-sensitive G-proteins Gi and Go. The a2ARs
act mainly by inhibiting neuronal firing and release norepi-
nephrine (NE) and other neurotransmitters in the CNS, but
they are also involved in a wide range of functions in
peripheral tissues, such as modulation of NE release from
sympathetic nerves, smooth muscle contraction and meta-
bolic and endocrine regulation [32,33].
Our strategy to direct M1 and a2bAR expression involved
fusing the coding region of the human m1 and a2b gene to
nucleotide sequences involved in the regulation of bop gene
transcription and translation [34–36]. We have engineered
24 combinations of bop and m1-bop gene fusions, and 30
a2b-bop fusions with various carboxyl-terminal tag modifi-
cations and characterized their effect on gene expression.
Disruption of the bop gene carboxyl-terminal coding region,
by addition of nucleotide sequences coding for peptide tags,
leads to perturbation in the timing and amounts of accumu-
lation of bop mRNA and ultimately the levels of BR that
accumulate. Similar perturbations are observed when the tag
sequences are included into the carboxyl-terminal coding
region of m1-bop and a2b-bop fusion constructs. While
transient expression of a2bAR was observed, the fusions
that accumulated mRNA or protein did so at much lower
levels than that observed for the wild-type bop indicating that
additional determinants of high-level accumulation remain to
be identified.
2. Materials and methods
2.1. Molecular reagents
All chemicals and salts were reagent-grade and obtained
from standard biochemical suppliers. T4 DNA ligase and
various restriction endonucleases for cloning were pur-
chased from New England Biolabs (Beverly, MA) or from
Boehringer Mannheim (Indianapolis, IN). Amplitaq DNA
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polymerase was obtained from Perkin-Elmer (Norwalk,
CT). Custom oligo-deoxynucleotide primers for mRNA
probes and vector constructions were purchased from Gibco
(Life Technologies, Gaithersburg, MD).
[Ethyl-3H]RS79948-197 (specific activity 81.0 Ci/mmol)
and [3H]RX821002 (specific activity 67.0 Ci/mmol) were
obtained from Amersham Pharmacia Biotech. [Methyl-
3H]Rauwolscine (specific activity 77.5 Ci/mmol) was pur-
chased from NEN Life Science Products. Phentolamine was
supplied from Sigma Chemicals. Optiphase III liquid scin-
tillation cocktail and glass fiber filtermat were supplied by
Perkin-Elmer Life Sciences Wallac Ltd.
Electrophoresis-grade agarose for DNA and RNA gel
electrophoresis was from FMC Corporation (Rockland,
ME). Nylon Hybond membranes (Amersham, MA) were
used for RNA gel blots. TRIzol reagent for RNA extraction
was from Life Technologies.
2.2. Carboxyl-terminal-tagged Bop
A 1.2-kilobase-pair DNA fragment containing the wild-
type bop gene coding region and transcriptional regulatory
elements was the basis of our expression strategy (pENDS
bopI; Ref. [34]). Five additional configurations of the bop
gene carboxyl-terminal coding region were constructed
(Table 1). An endogenous NotI DNA restriction site exists
within the downstream coding region of the bop gene, 73
base pairs (bp) upstream from an engineered BamHI cloning
site. The NotI–BamHI fragment contains codons for the last
five Bop amino acids, the translation stop codon, and 55 bp
of noncoding sequence (including the bop gene major
transcription terminator) [25]. Sequences coding for the
carboxyl-terminal HA and 6His tags (bop:HA and bop:6His,
respectively) were inserted immediately upstream of the
translation stop codon by polymerase chain reaction
(PCR). Oligo-directed mutagenesis (Transformer Site-Direc-
ted Mutagenesis kit, Clontech, Palo Alto, CA) was used to
introduce a ClaI restriction site immediately downstream of
the translation stop sequence in pENDS bop I. A positive
clone (pENDS bop:wt-ClaI) was confirmed by restriction
mapping and DNA sequencing. The NotI–ClaI restriction
fragment from pENDS bop:wt-ClaI was replaced with pairs
of complementary oligos to generate pENDS bop:6His-ClaI
and pENDS bop:HA-ClaI.
2.3. GPCR-Bop fusions
2.3.1. M1-Bop fusions
Four m1-bop fusions (A–D, Fig. 1) were constructed as
previously described [34,35]. The ‘‘A’’ fusion included the
coding region of the bop gene N terminus (including the
signal sequence and seven extra-helical amino acid residues)
and the last four amino acids of the bop gene C terminus.
The ‘‘B’’ fusion replaced the entire m1 extra-helical car-
Table 1
Carboxyl-terminal tag coding regions
* The single letter amino acid code is included above each codon to indicate the C-terminal protein sequence. Bolded amino acids identify engineered tags.
y Nucleotide sequences of downstream coding region. Restriction sites used in the cloning are underlined. The nucleotides shown in boldface were modified to
engineer a ClaI restriction site.
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boxyl-terminal coding region with the entire extra-helical
bop gene carboxyl-terminal coding region. The upstream
coding region was identical to the ‘‘A’’ fusion. The ‘‘C’’
fusion replaced the entire N-terminal coding region and the
first transmembrane helix of the m1 gene for that of the bop
gene. The downstream coding region was identical to the
‘‘A’’ fusion. The ‘‘D’’ fusion contained the N terminus using
a single unique restriction site within the coding region of
the m1 gene, the first transmembrane helix, and the carboxyl
terminal coding regions of the bop gene. The m1-bop A–D
fusions were further modified by subcloning NotI–BamHI
DNA fragments from the pENDS bop constructions con-
taining the six carboxyl-terminal coding regions into each of
the four pENDS m1-bop cloning vectors.
2.3.2. a2BAR-Bop fusions
Two a2b-bop fusions (analogous to B and D, Fig. 1) were
constructed. To aid in their construction, unique SalI (intro-
duced immediately downstream of the codon for the initiating
methionine), HindIII (introduced immediately downstream
of codon 41 and in-between the coding regions for helices A
and B), and XhoI (introduced immediately downstream of
codon 439) restriction sites were engineered by PCR. The
‘‘B’’ fusion (cloned on a SalI/XhoI fragment) contains the
coding region of the bop gene N terminus (including the
signal sequence and extra-helical amino acid residues; 17
residues from bop gene). The last 13 residues of the a2b C
terminus were replaced with the coding region for the 32-
residue bop gene C terminus. The ‘‘D’’ fusion (cloned on a
HindIII/XhoI fragment) replaces the entire N-terminal coding
region and first transmembrane helix of the a2b gene with
codons for the first 47 residues of the bop gene. The C-
terminal fusion is as in the ‘‘B’’ construct. These two
constructs were used as the basis for two deletions in the
third intracellular loop (i3) of a2bAR. The first deletion (d1)
made use of two fortuitous AccI restriction sites that flanked
nearly the entire i3 loop coding region. Digestion with AccI
and subsequent religation removed codons 192 through 364.
The second deletion (d2) was designed by homology to a
functional i3 loop deletion of the human M1 receptor [37].
The a2b contains a unique HinfI site immediately down-
stream of codon 218. A second HinfI site was engineered
after codon 356. Following digestion and religation, codons
218 through 362 were removed. These six a2b-bop fusions
were further modified by subcloning the bop:HA, bop:6His,
bop:6His-ClaI and bop:HA-ClaI carboxyl-terminal coding
regions into each. All 30 a2b-bop constructions were tested
for expression in H. salinarum.
H. salinarum expression vectors (pHex) were constructed
as described [34,35].
2.4. Bacterial strains, media and growth conditions
The Escherichia coli and H. salinarum strains used and
media and culture growth protocols have been described
[38]. H. salinarum culture media were supplemented with 60
Fig. 1. M1-Bop fusion proteins. M1 amino acids are in gray. Bop amino acids are in black. N- and C- refer to the amino and carboxyl termini, respectively.
Extracellular and intracellular sides of the membrane are indicated. (A) Minimal fusion. In this configuration, 20 Bop amino acids are fused at the N terminus of
M1. This contains the Bop signal sequence plus seven additional amino acids. Four Bop amino acids remain at the carboxyl-terminal portion of the fusion. (B)
C-terminal swap. This fusion adds the 23 C-terminal Bop amino acids after M1 helix 7. (C) First helix swap. The Bop helix 1 replaces the M1 helix 1. (D)
Combined first helix and C-terminal swap.
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AM scopolamine, an M1 antagonist, to stabilize expressed
M1 receptors [39], and with 100 AM phentolamine, an
a2bAR antagonist, to stabilize expressed a2bARs.
2.5. RNA probes
Digoxygenin-labeled cDNA probes were constructed by
PCR (Geniusk system, Boehringer Mannheim). A probe
specific for the H. salinarum 7S rRNA [40] was included
for each blot as an internal control for the total RNA loaded
in a gel sample. Densitometric ratios of bop, or m1-bop, and
7S RNAs (bop/7S and m1/7S, respectively) were used to
compare the levels of mRNA accumulation.
Two bop probes were constructed. The first bop probe
was complementary to the entire bop gene coding region
(nucleotides 1, the first base of the codon for the initiating
methionine, through 825). The second bop pre-sequence
probe was complementary to the 5Vcoding region, nucleo-
tides 1–66. The m1 probes represent various portions of the
m1 coding region. A 970-bp m1 probe (referred to as M1),
complementary to the coding region of the m1 gene from
nucleotides 346–1316, was generated by PCR. Three addi-
tional m1 cDNA probes were generated. These included a
184-bp probe complementary to m1 sequence bases 56–228
(the M1 first helix), a 121-base probe complementary to
bases 233–342 (the M1 second helix), and a 94-base probe
complementary to bases 1255–1338 (the M1 seventh helix).
The m1 nucleotides were numbered from the first base of
the codon for the M1 amino-terminal methionine.
The m1B:wt construction (e.g. m1-bop gene ‘‘B’’ fusion
with a wild-type bop carboxyl-terminal coding region)
accumulated significant quantities of m1-bop mRNA.
Therefore, m1B:wt RNA samples were used in gel blot
assays to optimize the mixture of M1 and 7S probes that
would allow ratiometric RNA quantification. Once the
appropriate concentrations for M1 and 7S probes were
empirically determined, a large pool of combined M1
and 7S probes was generated. All subsequent m1-bop
mRNA Northern analyses were accomplished using ali-
quots from this probe pool. The pool of bop/7S probes
used for all bop gene Northern analyses was made in a
similar fashion.
The SalI/XhoI fragment from the a2bB fusion was
template for the cDNA probe used in all a2b-bop mRNA
Northern analyses. The a2bD:wt and a2bD:HA-Cla con-
structions (e.g. a2b-bop gene ‘‘D’’ fusions with WT and
HA-ClaI carboxyl-terminal coding regions, respectively)
accumulated significant quantities of a2b-bop mRNA.
Therefore, a2bD:wt and a2bD:HA-Cla RNA samples were
used as controls in the a2b-bop gel blot assays to compare
the levels of mRNA accumulation.
2.6. RNA isolation and analysis
RNA gel blots were performed to determine mRNA
induction time courses and the relative levels of mRNA
that accumulated. H. salinarum cell samples for RNA
analysis were collected from mid-log to late exponential
growth stages (A660 of 0.8–1.0). Total RNA was isolated
as described [38]. Nylon membranes with blotted RNAs
were prehybridized for 12 h followed by 12 h of hybrid-
ization with a mixture of 7S and bop, m1, or a2b probes
in Engler-Blum hybridization solution [0.25 M Na2HPO4,
1.0 mM EDTA, 20% sodium dodecyl sulfate (SDS), and
0.5% blocking reagent (pH 7.2, 65 jC)] with gentle
rocking. Subsequently, membranes were washed and
detected according to a modified Engler-Blum protocol
[41]. The modifications included an additional 15-min
wash in post-hybridization washing buffer (20 mM
Na2HPO4, 1.0 mM EDTA, 1.0% SDS) and an additional
15-min wash in washing buffer [0.1 M maleic acid, 3.0
M NaCl, 0.3% Tween (pH 8.0)]. The chemiluminescent
substrate CDP-Stark (NEN, Boston, MA) was used for
RNA detection.
Control samples on each m1-bop RNA gel blot included
m1B:wt, bop:wt and L33 (BR  ). m1B:wt mRNA was
included on each gel as a control for monitoring the
consistency of the probe mixture activity. Because the
bop:wt mRNA exhibited fortuitous cross-reactivity with
all m1 probes, it was used as an internal control for mRNA
size determination. Control samples on each a2b-bop RNA
gel blot included a2bB:HA-ClaI and a2bB:HA-ClaI (d1).
The bands representing full-length gpcr-bop mRNA was
determined using known RNA size standards: 23S rRNA
(2904 bases), 16S rRNA (1473 bases), 7S rRNA (288 bases)
and bop mRNA (849 bases). 23S and 16S rRNA sizes were
separately visualized by ethidium bromide staining (data not
shown). 7S rRNA and bop mRNA were visualized by
chemiluminescence of the gel blots.
Quantification of mRNA accumulation was accom-
plished by phosphor imaging (GS 525 Molecular Imager
System, Bio-Rad, Hercules, CA) and exposure of the same
chemiluminescent gel blots to Kodak X-OMAT AR films
(East Rochester, NY). Film images were captured using a
computer interfaced CCD camera (AlphaImager IS2000
System). The volumes of the bop or gpcr-bop and 7S RNA
bands were calculated (pixels area of band) using the
‘‘Volume Analysis’’ function in Multi-Analyst software
(Bio-Rad). The pixel volumes were used to determine
the bop/7S or m1/7S ratios. The calculated mRNA/7S
ratios, determined by either method, were in close agree-
ment (data not shown) and the average of the obtained
mRNA/7S ratios for a specific band was used for subse-
quent analyses.
2.7. Membrane isolation
Three aliquots of 40–100 ml of cell culture were
collected between 24 and 72 h of cell culture growth for
protein analysis. Cells were sedimented at 8000 rpm for 20
min. The supernatant was decanted, and cell pellets were
resuspended in one-tenth volume basal salts plus scopol-
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amine methyl bromide or phentolamine. Cell suspensions
were lysed by resuspension in ice-cold incubation buffer
[TME: 50 mM Tris–HCl, 10 mM MgCl2, 1 mM EDTA (pH
7.4)] and Complete Proteinase Inhibitor Cocktail (one pellet
per 40 ml of cells, Boehringer Mannheim) and either 60 AM
scopolamine or 100 AM phentolamine. Cell suspensions
were homogenized with an Ultra-Turrax homogenizer
(Model T25, Janke and Kunkel, Staufen, Germany; setting
9500 rpm, 3 10 s). Raw membranes were pelleted at
100,000 g for 1 h. Pellets were resuspended in 1 ml of
TME buffer. Cell homogenate and membrane were kept at 4
jC and used immediately for protein estimation, ligand
binding and Western analysis. Protein concentration was
determined using the method of Bradford [42] with bovine
serum albumin as the reference standard.
2.8. BR spectroscopy
Membrane fractions containing purified BR (the PM)
were isolated by sucrose gradient centrifugation [18]. BR
concentration in the PM was quantified using a Perkin-
Elmer E18 spectrophotometer (e568BR = 62,700 M 1 cm 1;
Ref. [43]) and LabSphere RSA 150 mm light scattering
attachment in the diffuse transmittance mode.
2.9. Ligand binding
All incubations were performed in at least duplicate at
room temperature. Receptor binding was measured by
incubating 25–100 Ag of cell homogenate protein or mem-
brane protein with radioligands.
2.9.1. M1 radioligand binding assays
Membranes were resuspended in 50 mM sodium phos-
phate buffer containing 1.0 mM EDTA at pH 7.4 and
assayed for muscarinic receptors using 1.0 nM [3H]-N-
methylscopolamine [44].
2.9.2. a2B-AR radioligand binding assays
Homogenates were with [3H]radioligands in a total
volume of 100 or 500 Al in TME buffer. After 30 min, the
reactions were terminated by dilution in cold buffer and
rapid filtration through glass fibre filters using a Tomtec 96
Harvester Mach III (Tomtec, Inc., Hamden, CT) for 100 Al
incubations or a Brandel M-48R (Gaithersburg, MD, USA)
for 500 Al incubations in a cold room. Filters were washed
three times with 5 ml of cold buffer. The bound radioactivity
was determined in a MicroBeta liquid scintillation counter
(Perkin-Elmer Life Sciences Wallac Ltd.) at 28% efficiency
for 100 Al incubations and at 45% efficiency (Model 1410
counter, Perkin-Elmer Life Sciences Wallac Ltd.) for 500 Al
incubations. Specific binding was defined as the difference
between total and nonspecific binding, determined in a
parallel set of reactions but in the presence of an excess
of the subtype nonspecific adrenergic receptor antagonist
phentolamine (10 AM).
2.10. Bop 5Vpolyclonal antibodies and Western analysis
Bop N-terminal amino acids 1–22 comprise the upstream
coding region in all pENDS fusion vectors (Fig. 1, Ref.
[34]). Therefore, we generated polyclonal antibodies against
peptides representative of amino acids 15–22 to assist in the
detection of expressed receptors. The peptides (a generous
gift from Professor Ed Dratz, Department of Chemistry and
Biochemistry, Montana State University) were glutaralde-
hyde-coupled to keyhole limpet hemocyanin essentially as
described [45]. HRP, Inc. (Denver, PA) was contracted to
produce polyclonal antisera in New Zealand White female
rabbits.
Cell membranes were diluted to an A280 of 0.15, solubi-
lized in reducing SDS–polyacrylamide gel electrophoresis
(PAGE) gel loading buffer. For solubilization, isolated
membrane fractions were solubilized with 1.2% (w/v) N-
octyl-h-D-glucopyranoside (GERBU, Germany). The sam-
ples were incubated overnight at 4 jC on a rotating wheel.
The insoluble material was then removed by centrifugation
at 200,000 g for 2 h at 4 jC. Cell homogenates, solubi-
lized membrane fractions, or insoluble membrane fraction
were separated by 12% SDS-PAGE before being electro-
transferred onto polyvinylidene difluoride (PVDF) mem-
brane for immunostaining. For immunostaining, an affinity-
purified monoclonal antibody a2BAR-line 7G1 [46], or Bop
5Vpolyclonal antibodies were used as a primary antibody
(dilution of 1:5000). Immunoreactivity was detected using
horseradish peroxidase (HRP)-conjugated anti-mouse anti-
body (1:20,000) for IgG1 (Santa Cruz Biotechnology) or
HPR-conjugated anti-rabbit (Pierce, Rockford, IL) followed
by enhanced chemiluminescence ELC detection kit (Amer-
sham Pharmacia Biotech). Wild-type a2B-AR from Saccha-
romyces cerevisiae [47] and wild-type BR were used as
positive and negative controls, respectively. Membranes
isolated from L33 were mixed with known quantities of
purified PM to calibrate the detection sensitivity of the
polyclonal antibodies.
3. Results
3.1. Plasmid stability and culture growth
Southern analysis demonstrated that in all cases, the
transformed H. salinarum strains maintained the pHex
plasmids as autonomously replicating episomes at approx-
imately two to three copies per cell (data not shown).
Integration into the H. salinarum chromosome was never
observed (this study and Ref. [38]). The growth curves for
strain L33, L33 expressing the wild-type bop gene, the
carboxyl-terminally tagged bop genes, or the gpcr-bop
fusions were indistinguishable (data not shown). Therefore,
differences in expression levels cannot be ascribed to culture
growth or to the instability of the expression constructions,
in vivo.
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Fig. 2. C-terminal effects on bop gene expression. (A) Sucrose gradients used to purify WT, BR:HA, BR:6His, WT-ClaI, BR:HA-ClaI and BR:6His-ClaI.
Equivalent OD410 nm of whole-membrane preparations were subjected to sucrose density centrifugation. The OD410 nm is due to an endogenous membrane-
associated cytochrome shown previously to be linearly correlated with cell number [35]. The cytochrome is also used to visually identify the low-density
membrane fraction (indicated by *). The high-density band (indicated by arrow) is the PM (purified BR). The intensity at OD568 nm was used to determine the
quantity of BR that accumulated for each construction, as described in the text. (B) RNA gel blots used to determine bop mRNA:7S ratios for bop:wt, bop:HA,
bop:6His, bop:wt-ClaI, bop:HA-ClaI and bop:6His-ClaI. Total RNA samples were harvested at the culture growth time point indicated, purified, and blotted
onto nylon filters. The cDNA probes used were complementary to the entire bop gene coding region (top arrow) and the H. salinarum 7S RNA (bottom arrow).
The 7S RNAwas used as an internal control for gel loading. (C) Ratiometric analysis of bop:7S RNAs. The left curves show the means and standard deviations
for bop mRNA accumulation for three independent cultures expressing bop WT (open squares), bop:HA (open circles) and bop:6His (open diamonds). The
right curves show only the means for three independent cultures expressing bop:wt-ClaI (open squares), bop:HA-ClaI (open circles) and bop:6His-ClaI (open
diamonds).
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3.2. Effect of downstream coding region modifications on
bop gene expression
Alterations introduced into the carboxyl-terminal coding
region significantly affected bop gene expression. Extend-
ing the carboxyl-terminal coding region by six consecutive
histidines or nine amino acids HA epitope tag reduced BR
accumulation to 75% and 11% of wild type, respectively
(Fig. 2A, Table 2). Northern analysis demonstrated that the
bop gene mRNA levels were similarly affected (Fig. 2B,C).
The timing of accumulation of the bop:6His mRNA was
slightly delayed compared to that for the wild type and
accumulates to lower maximal levels. The bop:HA mRNA
accumulated at very reduced mRNA levels and maximal
accumulation was delayed by two generation times (>16 h).
The 2-bp change required to generate a ClaI DNA
restriction site downstream of the bop gene translation stop
signal had additional effects on expression (Fig. 2, Table 2).
In the context of the wild-type coding region, the ClaI site
modification slightly decreased the maximal levels of
Fig. 4. RNA gel blots of m1-bop mRNA for the C-terminal coding region
modifications. Only the gel blots for m1:wt, m1:6His and m1:6His-ClaI are
shown. Total RNA was isolated from cultures expressing the m1-bop gene
fusions at the following time points: (1 and 6) 38 h; (2 and 7) 49 h; (3 and
8) 62 h; (4 and 9) 72 h; (5 and 10) 88 h. The cDNA probes used were
complementary to the entire m1 gene coding region (top arrows) and the H.
salinarum 7S RNA (bottom arrows). The 7S RNA was used as an internal
control for gel loading. The bop mRNA (middle arrows) for the WT
construction showed fortuitous cross-reactivity to the M1 probe. Each panel
shows the effect of carboxyl-terminal coding region modification on all four
m1-bop gene fusions. Top panel is m1:wt; middle panel is m1:6His, lower
panel is m1:6His-ClaI. The symbols A, B, C and D represent the time
course of RNA accumulation for the four different m1-bop fusions. The
three right-most lanes are controls included on each blot: (11) m1B:wt, (12)
bop:wt and (13) L33.
Fig. 3. RNA gel blots used to compare sizes of the m1-bop fusion mRNAs.
The RNA sample shown for each m1-bop fusion was that determined from
the time course of induction experiment (Fig. 4) to accumulate maximal
full-length mRNA (top arrows). Ten micrograms of total RNA was loaded
in each well of the RNA gel blot. The fusions are in the order A, B, C, D,
for the carboxyl-terminal coding region fusions WT, HA, 6His and 6His-
ClaI. m1-bop fusion mRNAwas identified using a cDNA probe containing
the entire m1 coding region. The bop mRNA (middle arrows) for the WT
construction showed fortuitous cross-reactivity to this probe. m1-bop fusion
mRNA (top arrows) was compared with the following RNA size standards,
included on the gel: 23S RNA 2904 bases; 16S RNA 1473 bases; bop wt
849 bases (middle arrows); 7S RNA 288 bases (lower arrows). The 23S and
16S RNA were visualized by ethidium bromide staining (not shown). The
size of the top band corresponds well with the full-length mRNA predicted
for each m1-bop fusion construction. The molecular origin of the
intermediate-sized m1 specific RNAs was not revealed from our studies.
L33 is the H. salinarum strain used for all the expression studies and no M1
probe cross-reactivity is evident.
Table 2
Effect of downstream coding region variations on BR accumulation
BR construction BR construction
with ClaI site
BR:WTa 13.4F 1.7b mg/lc 11.8F 1.3 mg/l
BR:HAd 1.5F 1.1 mg/l 2.1F1.4 mg/l
BR:6Hise 9.9F 1.9 mg/l 0
a BR:WT, BR with the wild-type carboxyl terminus.
b Values are reported as mean and standard deviation from three
independent 1.5 l H. salinarum cell cultures.
c BR concentration (milligrams per liter of cell culture) determined from
e568
BR = 62,700 M 1 cm 1 [43].
d BR:HA, BR with carboxyl-terminal HA tag.
e BR:6His, BR with carboxyl-terminal HA tag.
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mRNA and protein accumulation. bop:wt-ClaI mRNA
accumulation remained at maximal levels further into sta-
tionary phase. BR:HA-ClaI and bop:HA-ClaI mRNA accu-
mulated at slightly higher levels than BR:HA and bop:HA.
In contrast, the ClaI site modification in the context of the
6His tag reduced BR and mRNA accumulation to negligible
levels. Overall, the order of maximal accumulation of BR
and bop mRNA was WT zWT-ClaI>6HisHHA-
ClaIfzHAH6His-ClaI.
3.3. m1-bop and a2b-bop gene fusions
To determine the contribution of the downstream coding
region on heterologous gene expression, we introduced
sequences coding for the wild-type Bop carboxyl-terminus
(WT), WT-ClaI, HA, HA-ClaI, 6His and 6His-ClaI in the
four m1-bop gene fusions and the six a2b-bop fusions. All
54 constructions were confirmed by restriction mapping and
DNA sequencing and expressed in H. salinarum.
3.4. gpcr-bop mRNA
RNA gel blots were used to determine the timing and
accumulation of the gpcr-bop gene mRNAs. Total RNAwas
isolated from cells during late logarithmic to the early
stationary phase of culture growth. The experimentally
determined sizes of the full-length gpcr-bop fusion mRNAs
agreed well with the expected sizes of the full-length
mRNAs. We attempted to use the bop pre-sequence probe
to quantify the relative abundance of the bop and gpcr-bop
mRNAs. The pre-sequence probe detected the bop:wt
mRNA in 0.05 Ag total RNA (data not shown). Using 10
Ag total m1-bopB:wt RNA or a2bB:HA-ClaI RNA, no gpcr-
bop mRNAs were detected. Therefore, gpcr-bop mRNA
levels accumulate to significantly lower levels than the wild-
type bop mRNA.
3.4.1. m1-bop
The M1/7S probe mixture identified only the 7S rRNA in
L33 (Figs. 3 and 4). The M1 probe hybridized with the
bop:wt mRNA, generating a fortuitous internal size marker
useful for identification of full-length m1-bop mRNAs. m1-
bop mRNA accumulated for each of the m1-bop fusions.
The experimentally determined sizes of the full-length m1-
bop fusion mRNAs agreed well with the expected sizes of
the full-length m1-bop mRNAs.
3.4.2. m1-bop RNA conformers
M1 probe hybridization of total RNA from L33 express-
ing the m1-bop gene fusions revealed the presence of
multiple m1 specific RNA species (Figs. 3 and 4). Some
of the smaller m1-bop RNA species were abundant. Because
we have observed correspondence between BR accumula-
tion and bop gene mRNA accumulation, and anticipated a
Fig. 5. Time course of accumulation of m1-bop mRNA species. The ratios of m1 mRNA and 7S RNA are plotted versus time of induction. The panels on the
left quantify the M1/7S ratios for the total conformer (full-length m1-bop mRNA plus the apparent 800-bp m1-bop mRNA). The panels on the right quantify
the M1/7S ratios of the full-length m1-bop mRNA only. The symbols represent the different m1-bop fusions M1A (open squares), M1B (open diamonds), M1C
(open circles) and M1D (open triangles).
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similar correspondence for M1 expression, we attempted to
determine the origin of the smaller m1-bop RNA species. To
determine if the most pronounced band (apparent size
f 800 bp) was the result of mRNA degradation, a set of
m1 probes was made that were complementary to the coding
regions comprising the first, second, and seventh helix of
M1. All probes identified the 800-bp band, suggesting that it
is not a degradation product (data not shown). To determine
if the 800-bp band was an alternate conformation of full-
length m1 mRNA, a series of RNA denaturation conditions
was attempted. None of the denaturation protocols elimi-
nated the 800-bp band (data not shown). The overall trends
in m1-bop mRNA accumulation were the same whether m1-
bop/7S ratios for the full-length mRNA or the sum of the
800-bp and full-length m1-bop/7S ratios (hereafter termed
the total conformer, TC) were quantified (Fig. 5). Until we
can rule out that the 800-bp band is not full-length m1-bop
mRNA, or derived from it, all subsequent quantification of
m1-bop mRNA refers to the total conformer.
3.4.3. m1-bop mRNA accumulation
The bop:wt and m1B:wt RNA samples included on each
gel blot provided an estimate of the error in mRNA
quantification (Figs. 3 and 4). The mean and standard
deviation for all m1B:wt/7S and bop:wt/7S ratios were
1.01F 0.07 and 0.58F 0.04, respectively (n = 12), and
demonstrated that the m1 and 7S probe mixture showed
consistent activity.
Fig. 6. Time course of accumulation of a2b-bop mRNA. Only gel blots for a2bB:HA (panel 1), a2bB:HA-ClaI (panel 2) and a2bB:6His-ClaI (panel 3) are
shown. i3 refers to a full-length i3 loop. d1 and d2 refer to the i3 loop deletions as described in the text. Total RNAwas isolated at 37, 49, 62, 72 and 87 h of
culture growth. Blots were probed with a mixture of the a2b and 7S cDNA probes. 7S (indicated by the arrow) was used as a control for gel loading. Additional
controls were included on each blot. Panels 1–3 (lanes a and b) are total RNA isolated from bopI and L33, respectively. Lanes c include total RNA from
cultures expressing a2bB:HA-ClaI (panel 1) and a2bB:HA-ClaI (d1) (panel 2).
Table 3
Accumulation of a2:bop fusion mRNA
a2:bop mRNA
B D
Full-length WT  +
HA  
HA-ClaI + +
6His  
6His-ClaI  
d1 WT + +
HA  
HA-ClaI + ++
6His  +
6His-ClaI  
d2 WT + +
HA  
HA-ClaI + +
6His  +
6His-ClaI + + 
 mRNA was not observed to accumulate.
+ mRNA was observed to accumulate.
++ mRNA was observed to accumulate at levels higher than other
constructions.
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Comparisons of the M1/7S ratios for the different m1-
bop gene fusions revealed that both the extent of m1-bop
gene fusions and the carboxyl-terminal modifications
affected m1 mRNA accumulation. mRNA accumulation
was inducible for all constructions, detectable quantities of
m1-bop mRNA did not accumulate until the culture reached
mid-log phase of growth (Fig. 4). This induction is similar
to that observed for the wild-type bop (Fig. 2) [38,48–50].
3.4.4. a2b-bop mRNA
RNA gel blots were also used to determine the timing
and accumulation of the a2b-bop gene mRNAs. The a2b
probe identified only a2b-bop mRNA in transgenic samples
and as observed for m1-bop mRNA, accumulation was
inducible (Fig. 6). Accumulation of a2b mRNA is extremely
sensitive to the extent of the bop gene fusion and the
carboxyl-terminal coding region included (Table 3). A
remarkable example is a2bB:HA fusion (Fig. 6). Neither
is a2bB:HA (full-length i3 loop) or is a2bB:HA (d1)
accumulated detectable mRNA while a2bB:HA (d2) accu-
mulated significant quantities. Indeed, at least half of the 30
constructions appeared not to accumulate mRNA. Given the
extreme variability and low levels of mRNA that accumu-
lated, the remainder of the a2b mRNA analysis was qual-
itative rather than quantitative. Subsequent analysis of
receptor accumulation was performed only for those con-
structions that accumulated mRNA.
In general, the order of maximal accumulation of gpcr-bop
mRNAwas observed to be WT>WT-ClaIf 6His>HA>HA-
ClaI>6His-ClaI (Fig. 7, Table 3). These results are similar to
those observed for the effects of the same carboxyl-terminal
modifications on the levels of accumulation of bop mRNA
(Fig. 2) and indicate that the downstream coding region
contributes to RNA accumulation. The carboxyl-terminal
coding regions affording the highest levels ofm1-bopmRNA
accumulation were the WT and 6His (Fig. 7). The carboxyl-
Fig. 7. Time course of accumulation of m1-bop mRNA for the C-terminal coding region modifications. The ratios of m1 mRNA (total conformer) and 7S RNA
are plotted versus time of induction. Each panel represents a C-terminal modification for all m1-bop gene fusions WT, WT-ClaI, HA, HA-ClaI, 6His and 6His-
ClaI. The symbols represent the different m1-bop fusions M1A (open squares), M1B (open diamonds), M1C (open circles) and M1D (open triangles).
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terminal coding regions affording the highest levels of a2b-
bop mRNA accumulation are the WT, HA-ClaI and 6His
(Table 3).
3.4.5. Effect of bop gene coding region fusions on mRNA
accumulation
The patterns of the M1/7S ratios demonstrated that the
region of the fused bop gene coding region sequences and
the carboxyl-terminal region modifications contribute to
mRNA accumulation. The effect is not systematic. The
M1A chimeras with WT and 6His-ClaI carboxyl-terminal
coding regions had the lowest accumulation of mRNA. In
contrast, M1A chimeras with 6His and HA carboxyl-termi-
nal coding regions accumulated the highest levels of
mRNA. In the context of the WT and 6His-ClaI carboxyl-
terminal coding regions, the M1B, M1C and M1D fusions
were similar in the timing of induction and levels of mRNA
accumulation. The M1B fusion containing the 6His-ClaI
carboxyl terminus had the highest mRNA accumulation of
all fusions. In the context of the HA and 6His carboxyl
terminal coding regions, the M1B, -C and -D fusions
accumulated the least amount of mRNA. In more cases
than not, the fusions containing the entire bop gene car-
boxyl-terminal coding region accumulated the most mRNA.
3.5. GPCR accumulation
The timing of bop gene mRNA and BR accumulation is
coupled [38,49] and we anticipate a similar relationship for
the gpcr-bop fusions. Therefore, we used the results of the
gpcr-bop mRNA induction analyses to determine the times
at which to harvest cell samples for protein analysis.
Because maximal gpcr-bop mRNA levels are achieved
between 40 and 70 h of culture growth, we harvested cells
over this time period and prepared membranes for Western
analysis and ligand binding.
3.5.1. Westerns
Dilution series of membranes expressing known quanti-
ties of BR:WT revealed that the detection limits of the
amino-terminal polyclonal antibodies were 20 ng of BR
(data not shown). Western analysis of membranes isolated
from cultures expressing the M1-Bop:WT fusion proteins
were negative. Membranes isolated from cells expressing
a2bD:WT(d2) contained a recombinant protein specifically
recognized by the BR polyclonal antibody (Fig. 8). a2b-Bop
was not observed for all fusions that accumulated mRNA,
suggesting that receptors were expressed at levels below the
Fig. 8. Functional expression of a2bAR in H. salinarum whole membranes.
(A) mRNA gel blot of selected a2b-bop gene fusions. i3 refers to a full-
length i3 loop region. d1 and d2 refer to the i3 loop region deletions as
described in the text. Shown in the left panel are three D constructions
containing the WT bop C-terminal coding region. All have full-length a2b-
bop mRNA. Shown in the right panel are three constructions containing the
HA C-terminal coding region, and none have a2b-bop mRNA. (B) Crude
membranes were isolated, subjected to SDS gel analysis, and blotted on
nylon membranes as described. The bop N-terminal polyclonal antibody
was used as the primary antibody. Lanes 1 and 2 are membranes from the
positive controls BopI and BopHA, respectively. Lane 3 shows the
positions of the molecular weight markers. Lane 4 contains membranes
from the a2bD:WT (d2) construction. A positive Western band with a
molecular size appropriate for the a2bD:WT (d2) construction is observed
near 33 kDa. The smaller band (f 15 kDa) is likely a proteolytic fragment
of the expressed a2bAR. (C) Ligand binding activity of expressed a2bAR in
crude H. salinarum membranes. Rauwolscine binding was observed for
those a2bAR constructions that contained significant quantities of a2b-bop
mRNA or that were detected in the Western analysis. BR-containing crude
membranes were used as negative control. S. cerevisiae cell membranes
expressing WT a2bAR were used as positive control (a2). Duplicate
samples of a2b:WT (d1) and (d2) were observed to bind Rauwolscine with
10-fold lower affinity but at specific activities as high as 40 pmol/mg
membrane protein. Membranes from the a2b:HA constructions shown in
the right panel of A did not bind Rauwolscine.
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antibody detection limits or that receptor accumulation was
not stable.
3.5.2. Ligand binding
Ligand binding to membranes prepared from CHO cells
expressing M1 receptors showed normal Bmax and Kd (data
not shown, Ref. [44]). Ligand binding to L33 cell mem-
branes putatively containing the M1A:Bop and M1D:Bop
(WT and 6His carboxyl-terminal modifications) was neg-
ative (data not shown).
[3H]Rauwolscine bound specifically to membranes iso-
lated from some of the a2bAR constructs that accumulate
significant quantities of mRNA (Fig. 8). a2bD:WT(d2)
bound Rauwolscine at a level of about 40 pmol/mg of
membrane protein—a level comparable to that found in S.
cerevisiae (Fig. 8). As shown by Scatchard plots, this
binding affinity is at least 10 times weaker than that of
wild-type a2bAR expressed in human or yeast cells (data
not shown). The difference cannot be attributed to the i3
loop deletion, as Rauwolscine affinity was unperturbed for
a2b-AR (d2) expressed in human cells (data not shown).
4. Discussion
The molecular events that initiate GPCR-mediated signal
transduction are not well understood because the structural
correlates of receptor activation are largely unknown. The
desired structural characterization depends upon obtaining
milligram quantities of purified receptors. A logical approach
to generate a system for production of GPCRs is to convert a
naturally occurring membrane protein expression system to
general usage. The Archaeal system under development has
many advantages: H. salinarum make large quantities of an
endogenous membrane protein (BR), this prokaryote is
cultured utilizing techniques employed for E. coli [26,51],
cultures grow under aerophilic conditions that do not require
BR for viability, and membranes are quantitatively recovered
by centrifugation following hypotonic cell lysis. Work from
this laboratory has demonstrated that eubacterial and eukary-
otic genes can be expressed at nanogram to milligram levels
per liter under the control of the bop promoter [22,35]. Using
a bop gene fusion strategy, functional a2- and h2-adrenergic
receptors have now been expressed in H. salinarum at levels
as high as 40 pmol/mg of total membrane protein (Ref. [52];
current study).
While the chromophore retinal provides a useful screen
for BR expression, detection of GPCR expression will
require tagging strategies. The current work tested the
effect of peptide tag modifications on BR expression and
revealed that an important determinant of expression is
located in the downstream coding region of the bop gene.
Insertion of DNA coding for a nine-amino-acid HA tag
resulted in greater than 90% reduction in bop:HA mRNA
and BR:HA accumulation. In a separate construction, a
6His coding region resulted in a small reduction in
bop:6His mRNA and BR:6His accumulation. The resultant
perturbations of BR accumulation indicate that expression
is sequence dependent. Remarkably, the bop:6His-ClaI
construction resulted in a near-complete loss of mRNA
and protein, indicating an extreme sensitivity to the nucleo-
tide sequence in this region.
The variation observed in tagged bop gene expression is
not due to codon usage. The ClaI site was engineered down-
stream of the native translation stop sequence and the codons
for the 6His tag were not changed in bop:6His-ClaI. There-
fore, the nucleotide sequence in this coding region contrib-
utes to mRNA accumulation and/or protein accumulation by
mechanisms that are independent of codon usage preferences.
A similar linkage between the carboxyl terminal coding
region and angiotensin receptor expression has been
observed in mammalian cells [53]. Other observations have
shown that carboxyl terminal tag sequences can affect heter-
ologous gene expression in E. coli; but in contrast, the effect
was attributed to post-translational contributions [54]. Down-
stream coding region-dependent contributions to expression
were also observed during efforts to express the low-abun-
dance BR homologue Sensory Rhodopsin I (SRI) in H.
salinarum. SRI, under the control of the bop gene promoter,
engineered essentially as an ‘‘A’’ construction, was expressed
at 10% of BR levels. This level of expression was achieved
only after truncation of the SRI carboxyl-terminal coding
region [21]. SRI shares the same codon usage bias as BR
(greater than 65% G/C) so the reduced levels of expression,
again, cannot be attributed to codon usage preferences. Krebs
et al. [55] added a 6His tag to a similar SRI construction and
achieved f 20% of BR levels demonstrating, once again,
that the context of the tag environment can significantly
influence expression levels.
The tag coding regions used do not appear to have
perturbed, or introduced, a local nucleotide structure that
uniquely contributes to mRNA accumulation. The calcu-
lated melting temperature for all six carboxyl-terminal
coding regions (from NotI site through the major tran-
scription stop site) is 85.4F 0.6 jC. Alternatively, the bop
gene mRNA may form long-range nucleotide interactions
(and/or nucleic acid–protein interactions) that contribute
to its accumulation.
Inspection of the sequence of the wild-type bop mRNA
helps to rationalize that the coding region contributes to
gene expression. The wild-type bop mRNA is f 831
nucleotides, 786 (f 94%) of which are coding regions
[24]. The bop mRNA is essentially leaderless; it contains
two untranslated bases upstream of the codon for the
initiating methionine. There are only f 40 noncoding bases
between the translation stop and the major transcriptional
terminator [25]. If sequences other than the downstream
noncoding sequences contribute to mRNA accumulation
and translation, they must exist in the coding region. Our
expression strategy removes the majority of the bop gene
coding region. Any bop gene coding region determinants
that existed will thereby have been perturbed. To date, gpcr-
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bop gene fusion expression levels are at least an order of
magnitude less than that for BR [34–36], supporting our
hypothesis that the bop gene coding sequences contains
critical determinants of expression.
Because the modifications made to the downstream
coding region of the bop gene resulted in dramatic
differences in expression, we anticipated that these same
modifications would influence expression of the gpcr-bop
gene fusions. We found that the levels of m1-bop mRNA
accumulation depended on both the gpcr-bop gene fusion
used and on the carboxyl-terminal modification included.
Similar to that observed for bop gene expression, a
range of gpcr-bop mRNA accumulation was observed
with the carboxyl terminal preference of WT>6His>HA.
The total amount of gpcr-bop mRNA that accumulated
does not systematically correlate with the extent of the
bop gene coding region contained in each chimera. For
example, the m1-bop:D fusions, containing the most
extensive bop gene coding region fusion, did not accu-
mulate the highest levels of mRNA. However, in gen-
eral, the D fusions consistently accumulated significant
levels of mRNA.
While we have been able to manipulate the gpcr
mRNA levels by addition of bop gene and carboxyl-
terminal coding sequences, the engineering strategy used
was not adequate to achieve wild-type bop levels of
mRNA accumulation. The absence of detectable M1
receptors is presumably related to the low levels of
mRNA. The levels of the wild-type bop mRNA that
normally accumulate may result from noncontiguous
coding region sequence determinants remote from the
transcriptional promoter. It may be necessary to engineer
more extensive m1-bop coding region chimeras or to
pursue molecular evolution strategies to generate coding
sequences capable of mimicking bop gene determinants
of mRNA accumulation. Implementation of the latter
strategy is currently in progress.
The timing and the amounts of bop and m1-bop
mRNA that accumulated were observed to vary for the
different carboxyl-terminal coding regions. The wild-type
bop mRNA declined rapidly in the late stationary phase
of culture growth, suggesting that bop mRNA synthesis
is decreased or an increase in bop mRNA degradation. It
is interesting to note that even though BR:HA and
BR:HA-ClaI accumulated significant quantities of mRNA
in the late stationary phase of cell growth, neither
construction accumulated significant protein. This sug-
gests that timing of mRNA accumulation and translation
are coupled for bop gene expression. The low levels of
m1-bop mRNA that accumulated are likely a combination
of the timing of induction of transcription, transcription
termination and mRNA stability. The steady-state accu-
mulation observed for m1-bop containing the 6His coding
region indicates a role for the carboxyl-terminal coding
region in the termination of bop mRNA transcription, in
the stability of mRNA stability, or both. The differences
between the timing of mRNA accumulation for the bop
and m1-bop fusions illustrate a methodological lesson
from this work; analysis of heterologous gene mRNA
accumulation should be performed to design protein
harvesting strategies.
It is evident from immunoblots and ligand binding data
that there is unstable a2bAR:BR expression and that
[3H]Rauwolscine binds to the fusion proteins with low
affinity. The lower binding affinity of the fusion proteins
in H. salinarum might have numerous origins: (1) absence
of G proteins in H. salinarum, (2) different lipid composi-
tion of H. salinarum membranes, or (3) modifications at the
N and/or C termini of the receptor fusions influence the
gene expression or folding of a2B-AR. Indeed, studies to be
reported elsewhere demonstrated that the N-terminal mod-
ifications introduced here, but not the C-terminal modifica-
tions, perturb a2B-AR accumulation in CHO cells. Further
optimization of the N/C-terminal coding region of a2b-bop
WT constructs and expression studies are thus necessary for
high protein level production of functional intact receptor in
the H. salinarum system.
In conclusion, this work provides further insight into the
expression of non-native genes in a novel prokaryotic
expression system. We have demonstrated that H. salinarum
can express functional eukaryotic GPCRs and that specific
coding regions contribute to their potential for expression.
The coding region influence appears to be at the nucleotide
level and is not due to codon usage preferences. The
combinations of bop gene fusions and C-terminal coding
region modifications attempted did not result in systematic
improvements in receptor expression, indicating that
nucleotide sequence-dependent determinants of expression
are not local in nature. We have observed that for wild-type
BR, and thus likely for GPCR, mRNA and receptor accu-
mulation are tightly coupled and this coupling can be
perturbed by small changes in coding sequences. The
available BR N-terminal polyclonal antibodies will direct
our future studies on constructions containing poly-His
coding regions. Successful optimization of this strategy will
result in production of the amounts of receptor proteins
required to achieve a structure-based understanding of
GPCR function. In the process, principles of high-level
expression in the third domain of life, the Archaea, will
be revealed.
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